

Grazoprevir / Elbasvir Formulation

Version 5.2 Revision Date: 05/02/2017 SDS Number: 76219-00008 Date of last issue: 12/06/2016
Date of first issue: 03/17/2015

SECTION 1. IDENTIFICATION

Product name : Grazoprevir / Elbasvir Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - USA 1685
Telephone : 908-740-4000
Telefax : 908-735-1496
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical


SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with 29 CFR 1910.1200

Combustible dust

Carcinogenicity (Inhalation) : Category 2
Specific target organ systemic toxicity - repeated exposure (Oral) : Category 2 (Liver, Testes)

GHS label elements

Hazard pictograms : 

Signal Word : Warning

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.
H351 Suspected of causing cancer if inhaled.
H373 May cause damage to organs (Liver, Testes) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read

Grazoprevir / Elbasvir Formulation

Version 5.2 Revision Date: 05/02/2017 SDS Number: 76219-00008 Date of last issue: 12/06/2016
Date of first issue: 03/17/2015

and understood.
P260 Do not breathe dust.
P280 Wear protective gloves/ protective clothing/ eye protection/
face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/
attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste dis-
posal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Hazardous ingredients

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 5 -< 10
Grazoprevir	1350462-55-3	>= 5 -< 10
Elbasvir	1370468-36-2	>= 1 -< 5
Magnesium stearate	557-04-0	>= 1 -< 5
Titanium dioxide	13463-67-7	>= 0.1 -< 1

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical
advice immediately.
When symptoms persist or in all cases of doubt seek medical
advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : Wash with water and soap.
Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms : Contact with dust can cause mechanical irritation or drying of

Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2016
5.2	05/02/2017	76219-00008	Date of first issue: 03/17/2015

and effects, both acute and delayed	:	the skin. Dust contact with the eyes can lead to mechanical irritation. Suspected of causing cancer if inhaled. May cause damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists.
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Metal oxides Chlorine compounds Nitrogen oxides (NO _x)
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.
Environmental precautions	:	Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for	:	Sweep up or vacuum up spillage and collect in suitable

Grazoprevir / Elbasvir Formulation

Version 5.2 Revision Date: 05/02/2017 SDS Number: 76219-00008 Date of last issue: 12/06/2016
 Date of first issue: 03/17/2015

containment and cleaning up container for disposal.
 Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
 Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
 Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
 Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
 Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.
 Do not swallow.
 Avoid contact with eyes.
 Avoid prolonged or repeated contact with skin.
 Handle in accordance with good industrial hygiene and safety practice.
 Minimize dust generation and accumulation.
 Keep container closed when not in use.
 Keep away from heat and sources of ignition.
 Take precautionary measures against static discharges.
 Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.
 Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Ingredients	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total)	15 mg/m ³	OSHA Z-1

Grazoprevir / Elbasvir Formulation

Version 5.2 Revision Date: 05/02/2017 SDS Number: 76219-00008 Date of last issue: 12/06/2016
 Date of first issue: 03/17/2015

		dust)		
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1
Grazoprevir	1350462-55-3	TWA	25 µg/m ³ (OEB 3)	Merck
		Wipe limit	250 µg/100 cm ²	Merck
Elbasvir	1370468-36-2	TWA	100 µg/m ³	Merck
Magnesium stearate	557-04-0	TWA	10 mg/m ³	ACGIH
Titanium dioxide	13463-67-7	TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA	10 mg/m ³ (Titanium dioxide)	ACGIH

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
 Minimize open handling.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection
 Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2016
5.2	05/02/2017	76219-00008	Date of first issue: 03/17/2015

disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : Ensure that eye flushing systems and safety showers are located close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	white
Odor	:	No information available.
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available

Grazoprevir / Elbasvir Formulation

Version 5.2 Revision Date: 05/02/2017 SDS Number: 76219-00008 Date of last issue: 12/06/2016
Date of first issue: 03/17/2015

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Dust can form an explosive mixture in air.
Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Ingredients:**Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Grazoprevir / Elbasvir Formulation

Version 5.2 Revision Date: 05/02/2017 SDS Number: 76219-00008 Date of last issue: 12/06/2016
Date of first issue: 03/17/2015

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

Grazoprevir:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Elbasvir:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 1,000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,500 mg/kg
Assessment: The substance or mixture has no acute oral toxicity

Titanium dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Skin corrosion/irritation

Not classified based on available information.

Ingredients:**Cellulose:**

Result: No skin irritation
Remarks: Based on data from similar materials

Grazoprevir:

Result: No skin irritation

Elbasvir:

Species: reconstructed human epidermis (RhE)
Result: No skin irritation

Titanium dioxide:

Species: Rabbit

Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2016
5.2	05/02/2017	76219-00008	Date of first issue: 03/17/2015

Result: No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Ingredients:**Cellulose:**

Result: No eye irritation

Remarks: Based on data from similar materials

Grazoprevir:

Species: Bovine cornea

Result: No eye irritation

Elbasvir:

Species: Bovine cornea

Result: No eye irritation

Titanium dioxide:

Species: Rabbit

Result: No eye irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Ingredients:**Cellulose:**

Test Type: Local lymph node assay (LLNA)

Routes of exposure: Skin contact

Species: Mouse

Method: OECD Test Guideline 429

Result: negative

Remarks: Based on data from similar materials

Grazoprevir:

Test Type: Local lymph node assay (LLNA)

Routes of exposure: Dermal

Result: Not a skin sensitizer.

Elbasvir:

Test Type: Local lymph node assay (LLNA)

Routes of exposure: Dermal

Species: Mouse

Assessment: Does not cause skin sensitization.

Grazoprevir / Elbasvir Formulation

Version 5.2 Revision Date: 05/02/2017 SDS Number: 76219-00008 Date of last issue: 12/06/2016
Date of first issue: 03/17/2015

Magnesium stearate:

Routes of exposure: Skin contact
Result: negative

Titanium dioxide:

Test Type: Local lymph node assay (LLNA)
Routes of exposure: Skin contact
Species: Mouse
Result: negative

Germ cell mutagenicity

Not classified based on available information.

Ingredients:**Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

Grazoprevir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

: Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Elbasvir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

: Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)

Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2016
5.2	05/02/2017	76219-00008	Date of first issue: 03/17/2015

Species: Rat
Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Result: negative

Carcinogenicity

Suspected of causing cancer if inhaled.

Ingredients:

Titanium dioxide:

Species: Rat
Application Route: inhalation (dust/mist/fume)
Exposure time: 2 Years
Method: OECD Test Guideline 453
Result: positive
Remarks: The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in inhalation studies with animals.

IARC

Group 2B: Possibly carcinogenic to humans

Titanium dioxide 13463-67-7

OSHA

No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP

No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Ingredients:

Grazoprevir:

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 400 mg/kg body weight
Result: negative

Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2016
5.2	05/02/2017	76219-00008	Date of first issue: 03/17/2015

Test Type: Multi-generation study
 Species: Rat
 Application Route: Oral
 Fertility: NOAEL: 400 mg/kg body weight
 Result: No effects on fertility., No effects on fetal development.

Effects on fetal development : Test Type: Embryo-fetal development
 Species: Rat
 Application Route: Oral
 Embryo-fetal toxicity.: NOAEL: 200 mg/kg body weight
 Result: No effects on fetal development.

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Oral
 Embryo-fetal toxicity.: NOAEL: 200 mg/kg body weight
 Result: No effects on fetal development.

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Intravenous
 Embryo-fetal toxicity.: NOAEL: 100 mg/kg body weight
 Result: No effects on fetal development.

Elbasvir:

Effects on fertility : Test Type: Fertility/early embryonic development
 Species: Rat, male and female
 Application Route: Oral
 Fertility: NOAEL: 1,000 mg/kg body weight
 Result: No effects on fertility and early embryonic development were detected.

Effects on fetal development : Test Type: Embryo-fetal development
 Species: Rat
 Application Route: Oral
 Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
 Result: No effects on fertility and early embryonic development were detected.

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Oral
 Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
 Result: No effects on fertility and early embryonic development were detected.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Liver, Testes) through prolonged or repeated exposure if swallowed.

Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2016
5.2	05/02/2017	76219-00008	Date of first issue: 03/17/2015

Ingredients:

Grazoprevir:

Target Organs: Liver, Testes

Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Ingredients:

Cellulose:

Species: Rat

NOAEL: > 5,000 mg/kg

Application Route: Ingestion

Exposure time: 90 Days

Remarks: Based on data from similar materials

Grazoprevir:

Species: Rat

NOAEL: 400 mg/kg

Application Route: Oral

Exposure time: 30 Days

Remarks: No significant adverse effects were reported

Species: Rat

NOAEL: 400 mg/kg

Application Route: Oral

Exposure time: 180 Days

Remarks: No significant adverse effects were reported

Species: Dog

NOAEL: 15 mg/kg

LOAEL: 100 mg/kg

Application Route: Oral

Exposure time: 270 Days

Target Organs: Liver, Testes, Blood, Bone marrow, gallbladder, spleen

Species: Mouse

NOAEL: 200 mg/kg

LOAEL: 500 mg/kg

Application Route: Oral

Exposure time: 90 Days

Target Organs: Liver, Kidney, Blood

Species: Dog

NOAEL: 20 mg/kg

LOAEL: 600 mg/kg

Application Route: Oral

Exposure time: 30 Days

Target Organs: Testes, Blood

Species: Monkey

NOAEL: 10 mg/kg

Exposure time: 8 Days

Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2016
5.2	05/02/2017	76219-00008	Date of first issue: 03/17/2015

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Ingredients:

Cellulose:

- Toxicity to fish : LC50 (Cyprinus carpio (Carp)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: Based on data from similar materials
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: Based on data from similar materials
- Toxicity to algae : EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Grazoprevir:

- Toxicity to fish : LC50 (Cyprinodon variegatus (sheepshead minnow)): > 10 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility.
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.
- LC50 (Americamysis): 8.9 mg/l
Exposure time: 96 h
- Toxicity to algae : EC50 (Pseudokirchneriella subcapitata (green algae)): > 10 mg/l
Exposure time: 72 hrs
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.
- NOEC (Pseudokirchneriella subcapitata (green algae)): 10 mg/l
Exposure time: 72 hrs
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.
- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.98 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility.

Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2016
5.2	05/02/2017	76219-00008	Date of first issue: 03/17/2015

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 5 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 1.3 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Elbasvir:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 10 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility.

LC50 (Menidia beryllina (Silverside)): > 10 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.

LC50 (Americamysis): 7.7 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility.

Toxicity to algae : EC50 (Pseudokirchneriella subcapitata (algae)): > 0.081 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.081 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.0023 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.84 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility.

Grazoprevir / Elbasvir Formulation

Version 5.2 Revision Date: 05/02/2017 SDS Number: 76219-00008 Date of last issue: 12/06/2016
Date of first issue: 03/17/2015

M-Factor (Chronic aquatic toxicity) : 10

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

Titanium dioxide:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h

Toxicity to algae : EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l
Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Persistence and degradability**Ingredients:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Grazoprevir:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 66 %
Exposure time: 28 d

Elbasvir:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 37 %
Exposure time: 45 d

Magnesium stearate:

Biodegradability : Result: Not biodegradable.

Bioaccumulative potential**Ingredients:****Grazoprevir:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 7.62

Partition coefficient: n- : log Pow: 3.72

Grazoprevir / Elbasvir Formulation

Version 5.2 Revision Date: 05/02/2017 SDS Number: 76219-00008 Date of last issue: 12/06/2016
Date of first issue: 03/17/2015

octanol/water

Elbasvir:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 82
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 6.54

Mobility in soil**Ingredients:****Grazoprevir:**

Distribution among environmental compartments : log Koc: 4.01

Elbasvir:

Distribution among environmental compartments : log Koc: 5.24

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Elbasvir)
Class : 9
Packing group : III
Labels : 9

IATA-DGR

UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Elbasvir)

Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2016
5.2	05/02/2017	76219-00008	Date of first issue: 03/17/2015

Class	: 9
Packing group	: III
Labels	: Miscellaneous
Packing instruction (cargo aircraft)	: 956
Packing instruction (passenger aircraft)	: 956

IMDG-Code

UN number	: UN 3077
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Elbasvir)

Class	: 9
Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F
Marine pollutant	: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

UN/ID/NA number	: UN 3077
Proper shipping name	: Environmentally hazardous substance, solid, n.o.s. (Elbasvir)
Class	: 9
Packing group	: III
Labels	: CLASS 9
ERG Code	: 171
Marine pollutant	: yes(Elbasvir)
Remarks	: Above applies only to containers over 119 gallons or 450 liters., Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards	: Fire Hazard Chronic Health Hazard
-----------------------------	--

Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2016
5.2	05/02/2017	76219-00008	Date of first issue: 03/17/2015

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

D-mannitol	69-65-8
Hydroxypropylmethylcellulose	9004-65-3
Croscarmellose sodium	74811-65-7
Sodium chloride	7647-14-5
Polyvinylpyrrolidone / Vinyl Acetate Copolymer	25086-89-9
Cellulose	9004-34-6
D-Glucose, 4-O-.beta.-D-galactopyranosyl-, monohydrate	64044-51-5
Grazoprevir	1350462-55-3
Elbasvir	1370468-36-2

California Prop. 65

WARNING! This product contains a chemical known in the State of California to cause cancer.

Titanium dioxide	13463-67-7
tert-Butyl-4-methoxyphenol	25013-16-5

California Permissible Exposure Limits for Chemical Contaminants

Cellulose	9004-34-6
Magnesium stearate	557-04-0

The ingredients of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined


Grazoprevir / Elbasvir Formulation

Version 5.2 Revision Date: 05/02/2017 SDS Number: 76219-00008 Date of last issue: 12/06/2016
 Date of first issue: 03/17/2015

SECTION 16. OTHER INFORMATION

Further information

NFPA:



HMIS® IV:

HEALTH	*	2
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA	:	8-hour time weighted average

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); EC_x - Concentration associated with x% response; EHS - Extremely Hazardous Substance; EL_x - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErC_x - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC₅₀ - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC₅₀ - Lethal Concentration to 50 % of a test population; LD₅₀ - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office

Grazoprevir / Elbasvir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/06/2016
5.2	05/02/2017	76219-00008	Date of first issue: 03/17/2015

of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 05/02/2017

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8